CANTATA EvaluatorSM for ZVRA

Methodology  
© 2024 BreakoutWatch.com
New CE:  
Company Information
Symbol: ZVRA
Company: Zevra Therapeutics, Inc.
Company Description:
Stock is Optionable: No
SEC Filings Edgar Online
General Due Diligence and Earnings Date Info: Due Diligence
Exchange: NASDAQ
CANTATA Evaluation for 11/21/2024
CE Zone
(Methodology)
 Time- liness CET CEF CE* Industry Industry
Rank 		Industry
Score
4-2 0/2 7.94 / 7 4.3 / 11 12.24 /18 Biotechnology 80 / 215 71 / 100
*Excluding Timeliness points
Timeliness
Item Data Points Maximum
Possible
1
Currently listed on CwH, DB, HTF or SQZ watchlists
0 1
2
Broke out in last 5 days and within 5% of BoP
0 1
 
Total Timeliness Points
 0 2
CANTATA Evaluation Technical (CET)
Item Data Points Maximum
Possible
1 Price relative to 50 and 200 day moving averages; 50 day relative to 200 day moving average
Last Close: $ 8.97
50 dma $ 8.09
200 dma $ 6.32
2.53 3
2 Relative Strength Rank
RS 90
2.72 3
3 Rank in Industry
Rank in Industry 74
# of stocks in Industry 601
0.88 1
4 Price relative to 52 week high
% off 52 week high 3.24 %
1.00 1
5 Up/Down Ratio
Up/Down Ratio: 1.6
0.80 1
  Miscellaneous Technical Data (no points assigned)
Beta 1.930
PE (vs. S&P 500) -9999999999.990 (-496770988.57 x)
5yr PE low - high -9999999999.990 - 0
n/a n/a
  Total Technical Points (CET) 7.94 9
CANTATA Evaluation Fundamentals (CEF)
1 Quarter over Quarter Earnings Growth
09/30/24 -0.695 vs. -0.299 [ -132.44 %]
06/30/24 -0.476 vs. -0.076 [ -526.32 %]
03/31/24 -0.398 vs. -0.383 [ -3.92 %]
12/31/23 -0.391 vs. 0.167 [ -334.13 %]
0.00 1
2 Positive Quarterly Earnings 0.60 1
3 Quarterly Earnings Growth Acceleration 0.70 1
4 Year over Year Earnings Growth Rates
12/31/23 [ 0 %]    
12/31/22 [ 0 %]    
12/31/21 [ 0 %]    
12/31/20 [ 0 %]    
12/31/19 [ 0 %]    
0.00 1
5 Quarter over Quarter Sales Growth Rates
09/30/24 3.700 vs. 2.900 [ 27.59 %]
06/30/24 4.400 vs. 8.500 [ -48.24 %]
03/31/24 3.400 vs. 3.200 [ 6.25 %]
12/31/23 13.200 vs. 2.000 [ 560 %]
0.60 1
6 Quarterly Sales Growth Rate Acceleration 0.40 1
7 Forward Earnings Growth Rates
Est. EPS growth current Fiscal Yr to next 83.600 %
Est. EPS Growth Next Fiscal Yr to Following 314.400 %
1.00 1
8 Institutional Ownership
Number of Institutional Owners 117.000
Net shares purchased MRQ ('000)
Institutional Ownership Details  
0.50 1
9 Return on Equity (ROE)
ROE - TTM -168.45 %
0.00 1
10 Cash Flow:
Cash from operations MRQ
Earnings TTM 0
Cash from operations TTM
Cash flow above/below earnings TTM 0
0.50 1
11 Net Margins
12/31/23 -167.700%
12/31/22 -263.500%
12/31/21 -29.900%
0.00 1
  Miscelleneous Fundamental Data (no points assigned)
Financial Overview
Long term debt to equity 85.100 %  
Current Fiscal Year End 12/31/24  
Yearly Sales ('000) 12/31/23 27.500
      12/31/22 10.200
      12/31/21 28.700
      12/31/20 13.300
      12/31/19 12.800
n/a n/a
  Total Fundamental Points (CEF) 4.30 11
  Total CANTATA Evaluation Points 12.24 20